Assessing the impact of COVID-19 on liver cancer management (CERO-19).

ABSTRACT:

Background & aims

The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.

Methods

An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave.

Results

Ninety-one centres expressed interest to participate a

SUBMITTER: Munoz-Martinez S 

PROVIDER: S-EPMC7901294 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature